Celgene Inc., in cooperation with Health Canada, has announced important new safety information concerning Thalomid that has been added to the drug’s product monograph. Health Canada, in a press release, describes Thalomid as an immunomodulatory agent indicated for the treatment of patients 65 years of age or older with previously untreated multiple myeloma, in combination with melphalan and prednisone (MPT).
The updated safety information informs patients that “second primary malignancies...
Read Full Story